eosinophilic asthma

From Aaushi
Jump to navigation Jump to search

Laboratory

Management

Notes

  • editorialist notes that asthma exacerbations decreased by 50% with placebo in one study suggesting that frequent monitoring of patients may lead to better control without the need for expensive biologic therapy[1]

More general terms

Additional terms

References

  1. 1.0 1.1 1.2 Ortega HG et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014 Sep 8; PMID: https://www.ncbi.nlm.nih.gov/pubmed/25199059
    Bel EH et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014 Sep 8 PMID: https://www.ncbi.nlm.nih.gov/pubmed/25199060
    Nair P Anti-interleukin-5 monoclonal antibody to treat severe eosinophilic asthma. N Engl J Med 2014 Sep 8 PMID: https://www.ncbi.nlm.nih.gov/pubmed/25197762
  2. Castro M, Corren J, Pavord ID et al Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. May 21, 2018 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29782217 Free full text https://www.nejm.org/doi/full/10.1056/NEJMoa1804092
  3. 3.0 3.1 Medical Knowledge Self Assessment Program (MKSAP) 17, American College of Physicians, Philadelphia 2015
  4. 4.0 4.1 From The Medical Letter on Drugs and Therapeutics Benralizumab (Fasenra) for Severe Eosinophilic Asthma. JAMA. 2018;319(14):1501-1502 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29634828 https://jamanetwork.com/journals/jama/fullarticle/2678013